iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. More Details
Flawless balance sheet with concerning outlook.
Share Price & News
How has iRhythm Technologies's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IRTC is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: IRTC's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: IRTC underperformed the US Medical Equipment industry which returned 35.7% over the past year.
Return vs Market: IRTC underperformed the US Market which returned 39% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is iRhythm Technologies's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StIs iRhythm Technologies (NASDAQ:IRTC) Using Debt In A Risky Way?
2 months ago | Simply Wall StThese Analysts Think iRhythm Technologies, Inc.'s (NASDAQ:IRTC) Sales Are Under Threat
3 months ago | Simply Wall StIs iRhythm Technologies' (NASDAQ:IRTC) Share Price Gain Of 131% Well Earned?
Is iRhythm Technologies undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate IRTC's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate IRTC's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: IRTC is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: IRTC is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IRTC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IRTC is overvalued based on its PB Ratio (6x) compared to the US Medical Equipment industry average (4.6x).
How is iRhythm Technologies forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IRTC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IRTC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IRTC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IRTC's revenue (10.4% per year) is forecast to grow faster than the US market (9.4% per year).
High Growth Revenue: IRTC's revenue (10.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IRTC is forecast to be unprofitable in 3 years.
How has iRhythm Technologies performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IRTC is currently unprofitable.
Growing Profit Margin: IRTC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IRTC is unprofitable, and losses have increased over the past 5 years at a rate of 21.7% per year.
Accelerating Growth: Unable to compare IRTC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IRTC is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (11.1%).
Return on Equity
High ROE: IRTC has a negative Return on Equity (-20.2%), as it is currently unprofitable.
How is iRhythm Technologies's financial position?
Financial Position Analysis
Short Term Liabilities: IRTC's short term assets ($336.1M) exceed its short term liabilities ($59.4M).
Long Term Liabilities: IRTC's short term assets ($336.1M) exceed its long term liabilities ($109.5M).
Debt to Equity History and Analysis
Debt Level: IRTC's debt to equity ratio (9.7%) is considered satisfactory.
Reducing Debt: IRTC had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IRTC has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: IRTC has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 18.7% each year
What is iRhythm Technologies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IRTC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IRTC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IRTC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IRTC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IRTC's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Doug Devine (50 yo)
Mr. Douglas J. Devine, also known as Doug, has been the Chief Financial Officer and Secretary at iRhythm Technologies, Inc. since June 22, 2020 and also serves as its Interim Chief Executive Officer since ...
CEO Compensation Analysis
Compensation vs Market: Doug's total compensation ($USD3.66M) is about average for companies of similar size in the US market ($USD3.71M).
Compensation vs Earnings: Insufficient data to compare Doug's compensation with company performance.
Experienced Management: IRTC's management team is considered experienced (4 years average tenure).
Experienced Board: IRTC's board of directors are considered experienced (5.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.4%.
iRhythm Technologies, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: iRhythm Technologies, Inc.
- Ticker: IRTC
- Exchange: NasdaqGS
- Founded: 2006
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$1.863b
- Shares outstanding: 29.30m
- Website: https://www.irhythmtech.com
Number of Employees
- iRhythm Technologies, Inc.
- 699 8th Street
- Suite 600
- San Francisco
- United States
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, a...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/23 02:36|
|End of Day Share Price||2021/06/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.